In FLT3‐ITD mutant AML, genetic or pharmacological suppression of PRMT1 markedly decreases FLT3‐ITD methylation levels and improves the effectiveness of tyrosine kinase inhibitors in eradicating leukemia progenitor cells. This evidence concerns the gene FLT3 and acute myeloid leukemia.